Kidney DiseasesPub Date : 2026-08-28eCollection Date: 2026-01-01DOI: 10.1159/kdd/adkag004
Andras T Deak, Klemens Pinter, Nikolaus Schreiber, Kathrin Eller, Alexander R Rosenkranz, Alexander H Kirsch
{"title":"Outcomes of Patients Deemed Ineligible for Kidney Transplantation.","authors":"Andras T Deak, Klemens Pinter, Nikolaus Schreiber, Kathrin Eller, Alexander R Rosenkranz, Alexander H Kirsch","doi":"10.1159/kdd/adkag004","DOIUrl":"https://doi.org/10.1159/kdd/adkag004","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney transplantation (KT) offers superior outcomes for patients with end-stage kidney disease (ESKD), yet many are excluded due to various reasons. Understanding exclusion factors and associated outcomes is essential.</p><p><strong>Methods: </strong>We retrospectively analyzed 835 ESKD patients from our center, including 152 evaluated between 1997 and 2017 and deemed ineligible for KT: 49 for nonmedical reasons (NMRs, e.g., nonadherence) and 103 for medical reasons (MRs, e.g., comorbidities or surgical contraindications). Outcomes were compared to a control group of 683 kidney transplant recipients (KTRs) between 2003 and 2017 from our center. Baseline characteristics were compared using Kruskal-Wallis and chi-square tests. Survival differences were assessed using inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis, and weighted Cox proportional hazards models.</p><p><strong>Results: </strong>Nonadherence and/or incomplete evaluation (32.2%) was the leading NMR, and surgical contraindication (20.4%) was the main MR for ineligibility. KTRs were younger (median age: 51 vs. 55 in NMR vs. 60 years in MR, respectively; <i>p</i> < 0.001) and had lower prevalence of diabetes mellitus (13.6% vs. 40.8% vs. 44.7%, <i>p</i> < 0.001), coronary artery disease (13.9% vs. 55.1% vs. 69.9%, <i>p</i> < 0.001) compared to the NMR and MR groups, respectively. IPTW-adjusted Kaplan-Meier analysis demonstrated the poorest survival in the MR group, followed by NMR, and the best in KTRs (<i>p</i> < 0.001). In weighted Cox models, MR (HR = 6.22, 95% CI: 3.44-11.2) and NMR (HR = 2.20, 95% CI: 1.21-3.98) groups had significantly higher mortality risk than KTRs.</p><p><strong>Conclusion: </strong>Nonmedical KT ineligibility is common and associated with inferior survival compared to KTRs. Targeted interventions to address modifiable barriers are warranted.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"834-841"},"PeriodicalIF":3.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-08-26eCollection Date: 2026-01-01DOI: 10.1159/kdd/adkag002
Ziming Wan, Hongwei Yang, Qiquan Lai, Xuejing Gao, Ling Chen, Xi Zhang, Hua Gan
{"title":"Predictors of Balloon-Assisted Arteriovenous Fistula Maturation: Importance of Intervention Timing and Blood Flow.","authors":"Ziming Wan, Hongwei Yang, Qiquan Lai, Xuejing Gao, Ling Chen, Xi Zhang, Hua Gan","doi":"10.1159/kdd/adkag002","DOIUrl":"https://doi.org/10.1159/kdd/adkag002","url":null,"abstract":"<p><strong>Introduction: </strong>Balloon-assisted maturation (BAM) improves the success rate of arteriovenous fistula (AVF) creation. However, the optimal timing of BAM and the factors influencing its success remain unclear. This study aimed to evaluate the clinical success rate of BAM and identify related influencing factors.</p><p><strong>Methods: </strong>A total of 991 patients undergoing BAM due to AVF immaturity were included (2017-2023) in this study. Data on patient demographics, AVF characteristics, procedural details, brachial artery ultrasound parameters, and preoperative serological indicators were collected. Logistic regression analyses identified factors associated with functional maturation.</p><p><strong>Results: </strong>The overall assisted maturation rate was 94.15%. An AVF creation-to-BAM interval of <90 days (odds ratio [OR] = 0.413, <i>p</i> = 0.006), prolonged thrombin time (OR = 0.209, <i>p</i> = 0.007), and elevated D-dimer levels (OR = 0.227, <i>p</i> = 0.006) were associated with a reduced maturation rate. A preoperative brachial blood flow ≥300 mL/min (OR = 2.886, <i>p</i> = 0.003) and a postoperative flow ≥830 mL/min (OR = 2.590, <i>p</i> = 0.002) were protective. Combining all 5 factors yielded an area under the curve of 0.786. In patients aged <65 years, upper arm AVF location (OR = 0.172, <i>p</i> = 0.022) and elevated gamma-glutamyl transferase (OR = 0.233, <i>p</i> = 0.009) were adverse factors. In patients aged ≥65 years, a low serum calcium level (OR = 0.403, <i>p</i> = 0.026) was an additional risk factor. Meanwhile, the AVF creation-to-BAM interval (age <65 years: OR = 0.307, <i>p</i> = 0.028; age ≥65 years, OR = 0.423, <i>p</i> = 0.045) and postoperative brachial flow (age <65 years: OR = 5.876, <i>p</i> = 0.001; age ≥65 years, OR = 2.516, <i>p</i> = 0.039) remained independent factors affecting AVF maturation.</p><p><strong>Conclusion: </strong>BAM is an effective intervention for immature AVFs. A longer interval from AVF creation to BAM and higher postoperative brachial flow are associated with increased AVF maturation rates, especially in younger patients.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"812-823"},"PeriodicalIF":3.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-08-25eCollection Date: 2026-01-01DOI: 10.1159/kdd/adkag003
Lele Qin, Caiyan Zheng, Zhijin Chen, Haofei Hu, Tingting Zeng, Xinya Wang, Zehan Zhang, Ting Lin, Li Zhang, Zhiming Ye
{"title":"Risk Factors for Renal Injury in Lung Cancer Patients Receiving Vascular Endothelial Growth Factor Inhibitor Therapy.","authors":"Lele Qin, Caiyan Zheng, Zhijin Chen, Haofei Hu, Tingting Zeng, Xinya Wang, Zehan Zhang, Ting Lin, Li Zhang, Zhiming Ye","doi":"10.1159/kdd/adkag003","DOIUrl":"https://doi.org/10.1159/kdd/adkag003","url":null,"abstract":"<p><strong>Introduction: </strong>Renal injury is an adverse effect of vascular endothelial growth factor (VEGF) inhibitor therapy. We investigated factors associated with renal injury and renal outcomes by VEGF inhibitor type in lung cancer.</p><p><strong>Methods: </strong>This retrospective cohort included 441 lung cancer patients treated with VEGF inhibitors. The primary cohort comprised 376 patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m<sup>2</sup>, negative dipstick proteinuria, and no hematuria at baseline; 65 patients underwent exploratory analysis. The primary composite renal outcome was incident proteinuria and/or eGFR decline >20% from baseline within 1 year. Cox models adjusted for clinical, tumor, and treatment covariates. Landmark and overlap-weighted sensitivity analyses were performed. Proteinuria and eGFR decline were analyzed separately.</p><p><strong>Results: </strong>The primary composite renal outcome occurred in 250 patients (66.5%); among patients with an event, the median time to first event was 92.0 days. Diabetes mellitus (adjusted hazard ratio [aHR], 1.89; 95% confidence interval [CI], 1.17-3.05), higher body mass index (BMI) (aHR per 1-kg/m<sup>2</sup> increase, 1.05; 95% CI, 1.00-1.09), and lower hemoglobin (aHR per 10-g/L increase, 0.86; 95% CI, 0.79-0.94) were independently associated with the primary outcome. VEGF inhibitor type was not associated with the primary outcome (overall <i>p</i> = 0.690), with similar overlap-weighted results. Incident proteinuria occurred in 120 patients (31.9%) and was associated with diabetes and lower hemoglobin; eGFR decline >20% occurred in 188 patients (50.0%) and was associated with lower hemoglobin. Platinum-containing chemotherapy showed a time-varying association with incident proteinuria.</p><p><strong>Conclusion: </strong>The primary composite renal outcome was common during the first year of VEGF inhibitor therapy. In the primary cohort, diabetes mellitus, higher BMI, and lower baseline hemoglobin were associated with this outcome, whereas no statistically significant association was observed for VEGF inhibitor type. These findings warrant validation in independent cohorts.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"854-868"},"PeriodicalIF":3.7,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-08-05eCollection Date: 2026-01-01DOI: 10.1159/000553569
Mashael Alzahrani, Douaa Sindi, Saeed M G Al-Ghamdi, Naser Omran Odah, Rana Alghamdi, Ahmed Alrefaei
{"title":"Comparison of Patiromer and Sodium Polystyrene Sulfonate for Chronic Hyperkalemia in Patients with Chronic Kidney Disease: A Prospective Cohort Study.","authors":"Mashael Alzahrani, Douaa Sindi, Saeed M G Al-Ghamdi, Naser Omran Odah, Rana Alghamdi, Ahmed Alrefaei","doi":"10.1159/000553569","DOIUrl":"10.1159/000553569","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic hyperkalemia in patients with chronic kidney disease (CKD) often limits the use of vital renin-angiotensin-aldosterone system inhibitors (RAASi).</p><p><strong>Methods: </strong>This prospective cohort study compared the efficacy and safety of patiromer (<i>n</i> = 40) versus sodium polystyrene sulfonate (SPS) (<i>n</i> = 40) for chronic hyperkalemia management in 80 adult CKD patients.</p><p><strong>Results: </strong>Over a 6-month follow-up, both agents effectively reduced serum potassium from similar baseline levels (patiromer: 5.73 ± 0.59 mmol/L; SPS: 5.62 ± 0.50 mmol/L) with no significant difference in efficacy (<i>p</i> > 0.05). However, key differences in the clinical impact on RAASi therapy emerged, alongside numerical but statistically nonsignificant differences in tolerability. Patients receiving patiromer had a significantly lower rate of RAASi therapy discontinuation compared to the SPS group (5.2% vs. 36.3%; <i>p</i> = 0.033), enabling continuation of guideline-directed medical therapy. A trend towards poorer compliance was noted in the SPS group (22.5% vs. 7.5%; <i>p</i> = 0.060). An exploratory analysis revealed that patiromer initiation significantly increased tacrolimus levels in post-kidney transplant recipients (<i>p</i> = 0.003), necessitating dose adjustments.</p><p><strong>Conclusion: </strong>While both agents showed comparable potassium-lowering efficacy, patiromer's numerical advantages in tolerability and significant benefit in maintaining RAASi therapy position it as a valuable therapeutic option in this high-risk population.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"842-853"},"PeriodicalIF":3.7,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-07-14eCollection Date: 2026-01-01DOI: 10.1159/000553450
Xueqi Wang, Jie Wang, Shuwen Zhou, Ziyao Yang, Zhiyu Duan, Yong Wang, Zheyi Dong, Jie Wu, Xiangmei Chen, Guangyan Cai
{"title":"Urinary Glucose Concentration as a Predictor of Proteinuria Reduction in Chronic Kidney Disease Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors.","authors":"Xueqi Wang, Jie Wang, Shuwen Zhou, Ziyao Yang, Zhiyu Duan, Yong Wang, Zheyi Dong, Jie Wu, Xiangmei Chen, Guangyan Cai","doi":"10.1159/000553450","DOIUrl":"https://doi.org/10.1159/000553450","url":null,"abstract":"<p><strong>Introduction: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are crucial in managing proteinuria in chronic kidney disease (CKD), yet individual responses vary. Whether urinary glucose excretion, a direct pharmacodynamic marker of SGLT2is, could predict proteinuria reduction efficacy remains unclear and has not been specifically investigated.</p><p><strong>Methods: </strong>We enrolled 277 CKD patients treated with empagliflozin (10 mg/day) between July 2024 and September 2025 at a single center, stratifying them into low (<46.4 mmol/L, <i>n</i> = 69) and high (≥46.4 mmol/L, <i>n</i> = 208) urinary glucose groups by 24-h urinary glucose levels after 3 months of treatment. We evaluated changes in proteinuria levels following 3 and 6 months of medication across the different urinary glucose groups. Changes in laboratory values over time were analyzed using paired Wilcoxon signed-rank tests.</p><p><strong>Results: </strong>Proteinuria was significantly reduced at both 3 (-0.42 g/24 h [95% confidence interval [CI]: -0.55 to -0.32]) and 6 months (-0.46 g/24 h [95% CI: -0.61 to -0.33]) after treatment initiation. After adjusting for covariates, urinary glucose excretion predicted proteinuria reduction from 3 to 6 months (β = 2.47, 95% CI: 0.49-4.45, <i>p</i> = 0.015), with higher urinary glucose correlating with greater proteinuria decline. The high urinary glucose group had significant proteinuria reduction from baseline at 3 and 6 months (<i>p</i> < 0.001), unlike the low group. Following propensity score adjustment for age, sex, body mass index, baseline estimated glomerular filtration rate (eGFR), and renin-angiotensin-aldosterone system inhibitors use, the high urinary glucose group had a significantly higher relative risk of ≥30% proteinuria reduction (risk ratio = 2.82, 95% CI: 1.20-6.65, <i>p</i> = 0.017), particularly in patients with baseline proteinuria ≥1 g/24 h. Urinary glucose concentration was weakly positively correlated with 6-month eGFR change (<i>r</i> = 0.17, <i>p</i> = 0.011).</p><p><strong>Conclusions: </strong>Urinary glucose concentration can serve as a predictor of SGLT2i-mediated proteinuria reduction, providing a practical clinical reference for personalized CKD management.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"759-771"},"PeriodicalIF":3.7,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13480981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-07-11eCollection Date: 2026-01-01DOI: 10.1159/000553548
Beiduo Lv, Zhaochen Guo, Zige Chen, Zhihong Liu, Hao Bao
{"title":"Enoxolone Alleviates Renal Fibrosis in Diabetic Kidney Disease by Inhibiting the Smad3-Smad4 Complex.","authors":"Beiduo Lv, Zhaochen Guo, Zige Chen, Zhihong Liu, Hao Bao","doi":"10.1159/000553548","DOIUrl":"https://doi.org/10.1159/000553548","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to explore the ameliorative effects of enoxolone on renal fibrosis in diabetic kidney disease (DKD) and elucidate its underlying molecular mechanisms, thereby proposing a novel candidate drug and providing a theoretical foundation for clinical anti-fibrotic therapy in DKD.</p><p><strong>Methods: </strong>We analyzed the single-cell transcriptome dataset GSE209781 and integrated it with the connectivity map database to identify potential therapeutic compounds for DKD. Molecular docking and surface plasmon resonance techniques were employed to verify the binding interaction between enoxolone and Smad3. In vitro experiments involved human renal tubular epithelial HK2 cells and primary mouse tubular epithelial cells derived from Smad3-knockout (Smad3-KO) mice, which were stimulated with high glucose and advanced glycation end-products (HG+AGEs). Co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), quantitative real-time polymerase chain reaction (qPCR), and Western blot analyses were conducted to assess the effects of enoxolone on the Smad3-Smad4 interaction, binding of Smad3 to the COL1A1 promoter, and expression of fibrotic genes. An in vivo streptozotocin-induced DKD mouse model with adeno-associated virus-mediated Smad3 overexpression was established to evaluate renal function, fibrosis, and associated molecular changes.</p><p><strong>Results: </strong>Enoxolone was identified as a key candidate capable of reversing collagen expression disorder in proximal tubular epithelial cells treated with high glucose and AGEs. It binds directly to the Arg292 site in the MH2 domain of Smad3 with a high affinity. Enoxolone significantly inhibited the formation of the Smad3-Smad4 complex, reduced the enrichment of Smad3 on the COL1A1 promoter, and downregulated COL1A1 expression. In DKD mice, enoxolone reduced blood urea nitrogen, serum creatinine, and renal hydroxyproline levels and alleviated collagen deposition and tubular injury, whereas Smad3 overexpression reversed these effects.</p><p><strong>Conclusion: </strong>Enoxolone targets Arg292 of Smad3, inhibiting Smad3-Smad4 complex formation and downstream pro-fibrotic gene transcription, thereby attenuating renal fibrosis in DKD. Enoxolone has emerged as a promising anti-fibrotic candidate for the treatment of DKD.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"788-798"},"PeriodicalIF":3.7,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13489610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-07-10eCollection Date: 2026-01-01DOI: 10.1159/000552705
Jie Mei, Yuk Kam Yau, Franco Wing Tak Cheng, Emily Tsui Yee Tse, Sydney Chi Wai Tang, Peter Tanuseputro, Cindy Lo Kuen Lam, Eric Yuk Fai Wan
{"title":"Risk Factors for All-Cause and Cause-Specific Mortality in Patients with Chronic Kidney Disease: Age-Specific Associations and Attributable Burden.","authors":"Jie Mei, Yuk Kam Yau, Franco Wing Tak Cheng, Emily Tsui Yee Tse, Sydney Chi Wai Tang, Peter Tanuseputro, Cindy Lo Kuen Lam, Eric Yuk Fai Wan","doi":"10.1159/000552705","DOIUrl":"https://doi.org/10.1159/000552705","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence regarding age-specific associations between risk factors and mortality in patients with chronic kidney disease (CKD) remains limited. We sought to investigate these age-specific associations and to measure their attributable burden on mortality.</p><p><strong>Methods: </strong>This population-based, retrospective cohort study included 576,677 patients in Hong Kong (73.5 ± 13.8 years, 2008-2020). We assessed all-cause and seven cause-specific mortality. Risk factors included six modifiable risk factors (smoking, blood pressure, fasting blood glucose/hemoglobin A1c, low-density lipoprotein cholesterol [LDL-C], and body mass index) and four major comorbidities (diabetes, cardiovascular disease [CVD], heart failure, and cancer). Using hazard ratios and population-attributable fractions (PAFs), we compared the associations and mortality burden of these risk factors across five age-groups (18 to ≥85 years).</p><p><strong>Results: </strong>During a median follow-up of 4.8 years, 329,098 (57.1%) patients died, with primary death causes being CVD (9.9%), cancer (9.9%), and kidney diseases (4.7%). Despite a higher absolute mortality risk in older patients, the relative risk of most risk factors declined with age. Collectively, all risk factors accounted for a higher mortality proportion in the youngest group (PAF: 44.3% [95% confidence interval: 35.3%, 52.0%]) than in the oldest group (22.6% [14.6%, 29.7%]). For patients aged 18-54, suboptimal LDL-C control (12.0% [8.0%, 15.8%]) was the leading risk factor, while CVD (12.6% [12.1%, 13.1%]) was the most influential factor in patients aged ≥75.</p><p><strong>Conclusion: </strong>The evaluated risk factors were associated with increased relative mortality risks in younger CKD patients. These findings underscore the importance of early management strategies, emphasizing LDL-C control in younger and CVD prevention in older CKD patients.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"799-811"},"PeriodicalIF":3.7,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2026-07-10eCollection Date: 2026-01-01DOI: 10.1159/000553501
Eiji Uza, Hirota Kida, Michioki Kuri
{"title":"Relationship of Renal Replacement Therapy to Cancer Site: A Hospital-Based Analysis in Osaka, Japan.","authors":"Eiji Uza, Hirota Kida, Michioki Kuri","doi":"10.1159/000553501","DOIUrl":"https://doi.org/10.1159/000553501","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer patients are at risk for acute kidney injury (AKI) due to anticancer agents, tumor lysis syndrome, sepsis, and contrast-induced nephropathy. Renal replacement therapy (RRT) is associated with longer hospital stays, higher healthcare costs, and significant healthcare resource consumption. Therefore, early detection of severe AKI requiring RRT and the implementation of preventive measures are crucial. We comprehensively evaluated the associations with RRT by cancer site among Japanese cancer patients undergoing treatment through use of Hospital-Based Cancer Registry (HBCR) data linked to administrative data in a multicenter cohort study.</p><p><strong>Methods: </strong>Patients were classified into three groups based on the timing of RRT after the initiation of cancer treatment: acute phase (≤30 days), post-acute phase (after 30 days), and no RRT. The hazard ratios (HRs) and subdistribution HRs for RRT incidence were evaluated by cancer site (colon, lung, stomach, liver, kidney, esophagus, pancreas, and hematologic malignancies) using Cox proportional hazards and Fine-Gray competing-risk models adjusted for patient characteristics, comorbidities, and diuretic use. The 1-year cumulative incidence of RRT was also calculated.</p><p><strong>Results: </strong>A total of 230,850 patients were analyzed. Among them, 386 patients received RRT at ≤30 days after cancer treatment initiation (acute phase), 479 patients received RRT at >30 days (post-acute phase), and 229,985 patients did not receive RRT. In the Cox proportional hazards regression model, the HRs for RRT were significantly higher in the acute phase among patients with colorectal cancer (HR: 1.72, <i>p</i> < 0.001), liver cancer (HR: 1.80, <i>p</i> = 0.006), kidney cancer (HR: 2.49, <i>p</i> < 0.001), and hematologic malignancies (HR: 4.06, <i>p</i> < 0.001) when compared according to cancer site. In the post-acute phase, only hematologic malignancies showed a significantly increased HR for RRT (HR: 2.65, <i>p</i> < 0.001). The 1-year cumulative incidence of RRT among all patients was 0.413%.</p><p><strong>Conclusion: </strong>The risk of RRT after cancer treatment was increased during the acute phase in patients with colorectal, liver, and kidney cancer and those with hematologic malignancies. Patients with hematologic malignancies always had a higher HR for RRT, but the HR was particularly high in the acute phase.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"772-787"},"PeriodicalIF":3.7,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13485296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and Efficacy of the First Mobile Intelligent Hemodialysis Platform in Mainland China: Protocol for a Single-Center Prospective Exploratory Study in Maintenance Hemodialysis Patients.","authors":"Renhua Lu, Yan Fang, Qisheng Lin, Yifei Lu, Yijun Zhou, Xiaojun Zeng, Tingting Liu, Wangshu Wu, Kewei Xie, Haifen Zhang, Shan Mou, Haijiao Jin, Zhaohui Ni, Leyi Gu","doi":"10.1159/000553515","DOIUrl":"https://doi.org/10.1159/000553515","url":null,"abstract":"<p><strong>Introduction: </strong>End-stage kidney disease (ESKD) is a growing global public health burden, with millions of patients dependent on maintenance hemodialysis (MHD). Conventional center-based MHD imposes significant constraints on patient flexibility, accessibility, and quality of life, while home hemodialysis faces substantial implementation barriers in China. Advances in digital health technologies - including artificial intelligence, internet of things (IoT), and real-time data analytics - offer opportunities to fundamentally transform dialysis care delivery. This study presents the protocol for the first clinical trial evaluating a mobile intelligent hemodialysis platform in mainland China.</p><p><strong>Methods: </strong>This is a prospective, single-center, exploratory clinical trial to be conducted at Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine. Twenty adult ESKD patients (aged 18-75 years) receiving regular MHD 3 times weekly for at least 3 months will be enrolled. Participants will undergo a single 4-h hemodialysis session on the mobile intelligent dialysis platform, a specialized medical vehicle integrating water purification, dialysis equipment, and an intelligent clinical decision support system across six functional zones. The primary endpoint is the successful session completion rate, defined as completion without platform-related technical failure or premature termination. Secondary endpoints include dialysis adequacy (urea reduction ratio ≥65%; Kt/V >1.2), hemodynamic stability, and pre- to post-dialysis changes in biochemical parameters. Safety assessments include continuous vital sign monitoring and adverse event grading according to Common Terminology Criteria for Adverse Events (CTC-AE) version 4.0. The study has been approved by the Ethics Committee of Ren Ji Hospital (approval number: LY2024-313-A) and registered in the Chinese Clinical Trial Registry (ChiCTR2500100356).</p><p><strong>Conclusion: </strong>This trial is expected to demonstrate that the mobile intelligent hemodialysis platform can achieve high session completion rates, adequate dialysis efficiency, and a safety profile comparable to conventional center-based dialysis. If validated, this platform has the potential to improve service accessibility, reduce indirect costs, enhance patient autonomy, and provide a resilient dialysis option in public health emergencies and disaster settings, representing a meaningful paradigm shift in dialysis care delivery.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"748-758"},"PeriodicalIF":3.7,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13480982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring the Role of Microbiota-Mediated Gut-Kidney Axis in Acute Kidney Injury: Immunomodulation and Therapy.","authors":"Litong Zhu, Shifeng Jiang, Qiulong Yan, Yujia Zhou, Yunfang Zhang, Hongquan Peng, Lili Zhou","doi":"10.1159/000552971","DOIUrl":"10.1159/000552971","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) remains a major clinical problem characterized by high morbidity and an increased risk of progression to chronic kidney disease (CKD). Immune cell infiltration and activation are important features of AKI; however, the upstream mechanisms that shape this inflammatory response are not fully understood. Emerging evidence suggests that gut microbiota dysbiosis and systemic immune activation may contribute to renal injury, but the functional significance of the gut-kidney axis in AKI pathogenesis remains to be further clarified.</p><p><strong>Summary: </strong>This review synthesizes current evidence regarding gut-kidney crosstalk in AKI, with a focus on the immunometabolic impact of microbiota-derived metabolites. We discuss the potential roles of short-chain fatty acids, indole derivatives, indoxyl sulfate (IS), p-cresol sulfate (PCS), and trimethylamine-N-oxide (TMAO) in regulating T and B lymphocytes, macrophages, neutrophils, and other immune cell populations. Importantly, we distinguish direct AKI-related evidence from findings extrapolated from CKD, uremic conditions, or broader microbiome-immunity studies. Potential therapeutic interventions, including pharmacological modulation and probiotic strategies aimed at restoring gut-kidney homeostasis, are also highlighted.</p><p><strong>Key messages: </strong>The gut-kidney axis is increasingly recognized as a potential contributor to immune-mediated injury and repair in AKI. However, the causal roles and temporal dynamics of several gut-derived uremic toxins, including IS, PCS, and TMAO, remain incompletely defined in AKI. By integrating direct AKI evidence with indirect evidence from CKD and broader microbiome-immunity studies, this review provides a more balanced conceptual framework for understanding renal immunopathology and identifying potential microbiome-targeted strategies to mitigate AKI and its progression to CKD.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"12 1","pages":"722-733"},"PeriodicalIF":3.7,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13441276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}